# OnCo record proviva-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/proviva-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "proviva-therapeutics" ;
  schema:name "Proviva Therapeutics"@en ;
  schema:alternateName "Proviva Therapeutics, Inc."@en, "博致生物"@en, "博致生物科技（上海）有限公司"@en ;
  schema:description "Proviva Therapeutics is testing PTX-912, an engineered form of the immune signal IL-2 designed to switch on mainly inside tumours, in an early trial in the United States for people with advanced solid tumours."@en ;
  schema:url <https://onco.cc/companies/proviva-therapeutics/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06190886>, <https://news.pedaily.cn/202403/530729.shtml>, <https://www.pharnexcloud.com/trz/trz_ded7210b75b2b633ad7fd29246debfb2>, <https://www.orbimed.com/portfolio/> ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/immunocytokines/>, <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/ptx-912/> .